



**Intellectual Property  
Technology Law**

1414 Raleigh Road, Suite 201  
Chapel Hill, NC 27517

P.O. Box 14329  
Research Triangle Park, NC 27709

Phone: (919)419-9350

Fax: (919)419-9354

[Info@iptl.com](mailto:Info@iptl.com) • [www.iptl.com](http://www.iptl.com)

#180  
ack  
10/2/02  
RPS  
9/27/02

# Fax

**To:** U.S. Patent and Trademark Office **From:** Marianne Fuierer

**Fax:** 703-746-3103 **Date:** September 27, 2002

**Phone:** **Pages:** (including this page) 37

**Re:** Response to November 8, 2001 Office Action **File:** 4121-115

Original Document to: ☐ Follow via Regular Mail ☐ Follow via Express Mail ☒ Not to be sent (unless requested)

**Comments:**

Examiner Shukla:

Attached is the response that we faxed on March 8, 2002 along with confirmation receipt from the USPTO.

Thank you for calling and checking on the filing of this response.

Marianne Fuierer

**CONFIDENTIALITY NOTE: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL AT THE ADDRESS SET OUT ABOVE.**

Sent by

U.S. Patent Application 09/446,808

Commissioner for Patents  
Washington, D.C. 20231

Sir:

This responds to the Office Action dated November 8, 2001 in the above-identified U.S. patent application.

An extension of time request under 37 CFR §1.136 is set forth in the penultimate paragraph of the REMARKS section hereof, extending the term for reply to the November 8, 2001 Office Action from February 8, 2002 to March 8, 2002.

In response to the Examiner's request for revision of the specification (see page 3, paragraph 5 of the November 8, 2001 Office Action), a substitute specification is enclosed in **APPENDIX A** hereof, complying with the requirements of 37 C.F.R. § 1.125(b), and a marked-up copy of the substitute specification is enclosed in **APPENDIX B** hereof, revised consistent with the Examiner's suggestions, and otherwise incorporating the amendments made herein. I hereby declare that this substitute specification submitted under the provisions of 37 CFR §1.125(b) contains no new matter (35 U.S.C. §132).

In response to the November 8, 2001 Office Action, please amend the application, as follows.

**IN THE TITLE**

Replace the Title: "Mammal with Inhibition of the Poly (ADP Ribose) Polymerase and Method For Using Same to Identify Cancerigenic Agents"

With --Mammal with Inhibition of the Poly (ADP Ribose) Polymerase and Method For Using Same to Identify Carcinogenic Agents--

**IN THE ABSTRACT**

Replace the originally filed Abstract of the Disclosure with the new Abstract of the Disclosure set forth in **APPENDIX C**. A marked-up version of the amended Abstract, showing the amendatory changes, is set forth in **APPENDIX D**.